Molecular Residual Disease After Definitive Chemoradiotherapy in Locally Advanced Head and Neck Cancer: Clinical Value and Optimal Timing for ctDNA Assessment.
Year: 2026
Type: article
Study design: Observational Study
Abstract: BACKGROUND: Accurate post-treatment assessment after definitive chemoradiotherapy (CRT) in locally advanced head and neck squamous cell carcinoma (LA-HNSCC) remains challenging due to limitations of standard imaging. We evaluated the diagnostic performance, prognostic value and optimal timing of circulating tumor DNA (ctDNA) for molecular residual disease (MRD) detection. METHODS: Seventy-four patients with LA-HNSCC treated with definitive CRT were prospectively enrolled. Plasma samples were collected before treatment, at 8 and 12 weeks after CRT, and during follow-up. ctDNA was analysed using a plasma-only methylation-based assay. Diagnostic performance for recurrence detection and associations with progression-free survival (PFS) and overall survival (OS) were evaluated and compared with 12-week PET/CT findings. RESULTS: Baseline ctDNA was detectable in 85.1% of patients. Among post-treatment timepoints, week-12 ctDNA showed the highest diagnostic accuracy for recurrence detection, with 69% sensitivity, 100% specificity, 100% positive predictive value, and 76% negative predictive value. Detectable week-12 ctDNA was associated with shorter PFS (HR, 6.44; 95% CI, 2.73-16.74; p<0.001) and OS (HR, 7.31; 95% CI, 2.80-22.31; p<0.001 ). Longitudinal ctDNA surveillance identified additional recurrences among patients with initially undetectable week-12 ctDNA. Exploratory analyses integrating PET/CT and ctDNA identified prognostically distinct PFS groups (log-rank P=0.033), with the greatest additional prognostic stratification observed among PET partial-responders. CONCLUSIONS: Plasma-only methylation-based ctDNA provided high-specificity prognostic information after definitive CRT in LA-HNSCC, particularly at week 12 and in PET partial-responders. ctDNA may complement PET/CT for post-treatment risk stratification, but should not be used as a stand-alone test to exclude recurrence.
Source: Clinical Cancer Research
Authors: Gema Bruixola, Jorge Martín-Arana, Francisco Gimeno-Valiente, Franz Villarroel-Espindola, Clara Alfaro-Cervelló, Delfina Dualde, Nuria Grimalt, Miguel García Bartolomé, Alonso García-Márquez, Belén Iglesias-Martinez, Francisco Martínez-Picó, Belén Martínez-Castedo, Blanca García-Micó, Daniel González. Camblor, Maria Eugenia Iglesias, Vicente Escorihuela García, María Maroñas, Jim Hayes, Andrés Cervantes, Noelia Tarazona
Language: English
Topic: Head and Neck Cancer Studies
Subfield: Otorhinolaryngology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Award: G3687076075
OpenAlex ID: W7235300800
